- Home
- ANNX vs IIF Comparison
ANNX vs IIF Comparison
Compare ANNX & IIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- IIF
- Stock Information
- Founded
- ANNX 2011
- IIF 1993
- Country
- ANNX United States
- IIF United States
- Employees
- ANNX N/A
- IIF N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- IIF Trusts Except Educational Religious and Charitable
- Sector
- ANNX Health Care
- IIF Finance
- Exchange
- ANNX Nasdaq
- IIF Nasdaq
- Market Cap
- ANNX 253.8M
- IIF 265.3M
- IPO Year
- ANNX 2020
- IIF N/A
- Fundamental
- Price
- ANNX $3.09
- IIF $26.74
- Analyst Decision
- ANNX Strong Buy
- IIF
- Analyst Count
- ANNX 4
- IIF 0
- Target Price
- ANNX $13.00
- IIF N/A
- AVG Volume (30 Days)
- ANNX 2.4M
- IIF 45.4K
- Earning Date
- ANNX 11-13-2025
- IIF 01-01-0001
- Dividend Yield
- ANNX N/A
- IIF 13.94%
- EPS Growth
- ANNX N/A
- IIF N/A
- EPS
- ANNX N/A
- IIF N/A
- Revenue
- ANNX N/A
- IIF N/A
- Revenue This Year
- ANNX N/A
- IIF N/A
- Revenue Next Year
- ANNX N/A
- IIF N/A
- P/E Ratio
- ANNX N/A
- IIF N/A
- Revenue Growth
- ANNX N/A
- IIF N/A
- 52 Week Low
- ANNX $1.29
- IIF $18.95
- 52 Week High
- ANNX $7.85
- IIF $24.41
- Technical
- Relative Strength Index (RSI)
- ANNX 60.42
- IIF 47.95
- Support Level
- ANNX $2.91
- IIF $26.54
- Resistance Level
- ANNX $3.38
- IIF $26.73
- Average True Range (ATR)
- ANNX 0.24
- IIF 0.33
- MACD
- ANNX 0.02
- IIF -0.01
- Stochastic Oscillator
- ANNX 61.87
- IIF 38.38
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.